metsera novo nordisk - Search News

Pfizer, Novo Nordisk and Metsera

Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk.

· 4h · on MSN

Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

· 5d · on MSN

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

· 7h

Metsera falls after accepting up to $10 billion sweetened buyout offer from Pfizer

Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.

· 8h

Novo Rises After Bowing Out of Metsera Takeover Battle

· 13h

Novo Nordisk shares rise after dropping Metsera bid

PharmExec

Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an amended acquisition proposal to Metsera for $62.20 per share, a total value of $7.2 billion. Shortly after receiving the amended proposal, Metsera’s board of directors suggested to stockholders to approved Pfizer’s acquisition. 3

STAT

The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's also taking on a lot of risk.

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.

Big Danish drugmaker Novo Nordisk (NVO 3.88%) reported its third-quarter results on Wednesday, Nov. 5. Although sales and earnings grew year over year, the company downgraded its

Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its blockbuster obesity drugs slows, leaving investors worried the firm is losing ground to U.

STAT

FTC raises concern about Novo Nordisk attempt to acquire obesity startup Metsera

The Federal Trade Commission has raised concerns about Novo Nordisk’s attempt to outbid Pfizer to acquire obesity startup Metsera, the latest complication in a dramatic bidding war between two pharma giants.